

## CLAIMS

## I Claim:

5           1. A non-nucleic acid probe having a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of: CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGC-CGC-AGA-GTT-TAA (Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8); TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9); CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq. ID No. 15); GGC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16); AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17); CAT-TGA-ACA-GAA-TTG-AAT (Seq. ID No. 18); GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-AAG-AAT (Seq. ID No. 25); TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID No. 26); ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-AGA (Seq. ID No. 42); GGC-CTC-AAA-

GAC-GTT-TAA (Seq. ID No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44);  
GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA  
(Seq. ID No. 46); TGC-AGA-GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-  
CAT-TCG-CAG (Seq. ID No. 48); AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49);  
5 CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA  
(Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-  
AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No.  
10 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-CCA-  
ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57); GCA-GAG-  
ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID  
15 No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-  
TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-  
TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63); TAC-CAA-GAG-GAA-TGT-TGC (Seq.  
ID No. 64); ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-  
ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-  
20 AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq.  
ID No. 69); CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70); AAC-TGA-ACG-  
CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No.  
72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-  
CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-  
TCT-AAC-TAA-TCA (Seq. ID No. 76); GTA-GTT-GTT-GAG-AAT-GAT (Seq. ID No.  
77); AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-  
25 CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-  
ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID  
No. 82); GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83); TCC-TGT-AAT-GTT-  
CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-  
30 TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-  
GG (Seq. ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-  
ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No.  
90); TGT-CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-  
AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93);  
AAC-TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT  
(Seq. ID No. 95); CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); GAA-GCC-TGC-

CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100); AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID No. 101); ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110); AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118).

2. The probe of claim 1, wherein the probing nucleobase sequence is exactly as represented in the claim.
3. The probe of claim 1, wherein the probing nucleobase sequence is 17-23 subunits in length.
4. The probe of claim 1, wherein the probe is unlabeled.
5. The probe of claim 1, wherein the probe is labeled with at least one detectable moiety.
6. The probe of claim 5, wherein the detectable moiety or moieties are selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound.
7. The probe of claim 1, wherein the probe is labeled with at least two independently detectable moieties.

8. The probe of claim 7, wherein the two or more independently detectable moieties are independently detectable fluorophores.

9. The probe of claim 1, wherein the probe is support bound.

5 10. A probe set comprising at least thirteen non-nucleic acid probes and which is suitable for detecting, identifying or enumerating human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18 in a sample.

10 11. The probe set of claim 10, wherein:

the one or more non-nucleic acid probes of the set specific for detecting human chromosome X have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

15 CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGC-CGC-AGA-GTT-TAA (Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8) and TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9);

20 the one or more non-nucleic acid probes of the set specific for detecting human chromosome Y have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

25 CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq. ID No. 15) and GCC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16);

30 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 1 have a probing nucleobase sequence, at least a portion of which is at

least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17) and CAT-TGA-ACA-GAA-TTG-AAT (Seq. ID No. 18);

5 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 2 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

10 GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-AAG-AAT (Seq. ID No. 25) and TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID No. 26);

15 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 3 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

20 ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-35) ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-AGA (Seq. ID No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-

AAG-AAT-CAT-TCG-CAG (Seq. ID No. 48); and AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49);

the one or more non-nucleic acid probes of the set specific for detecting human chromosome 6 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63) and TAC-CAA-GAG-GAA-TGT-TGC (Seq. ID No. 64);

the one or more non-nucleic acid probes of the set specific for detecting human chromosome 8 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq. ID No. 69) and CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70);

the one or more non-nucleic acid probes of the set specific for detecting human chromosome 10 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76) and GTA-GTT-GTT-GAG-AAT-GAT (Seq. ID No. 77);

the one or more non-nucleic acid probes of the set specific for detecting human chromosome 11 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

5 AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID No. 82) and GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83);

10 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 12 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

15 TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT (Seq. ID No. 95) and CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96);

20 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 16 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

25 GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100) and AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID No. 101);

30 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 17 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110) and AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111);

5 the one or more non-nucleic acid probes of the set specific for detecting human chromosome 18 have a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, 10 selected from the group consisting of:

15 TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT- 20 ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118).

25 12. The probe set of claim 11, wherein the probing nucleobase sequence of the probes of the set are exactly as represented in the claim.

30 13. The probe set of claim 11, wherein two or more probes of the set are independently detectable.

14. The probe set of claim 13, wherein one or more of the independently detectable probes are labeled with two or more independently detectable moieties.

35 15. The probe set of claims 13, wherein the independently detectable probes are used to distinguish between human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18.

16. The probe set of claim 10, wherein the two or more probes of the set are unlabeled.

40 17. The probe set of claim 10, wherein at least one probe of the set is labeled with a detectable moiety. 9

18. The probe set of claim 10, wherein the detectable moiety or moieties are selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound.

5

19. The probe set of claim 10, wherein *in-situ* hybridization is used to detect, identify or quantitate human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18 in the sample.

10

20. The probe set of claim 10, wherein the probe set is used to detect or identify chromosome related abnormalities.

15

21. The probe set of claim 20, wherein the probe set is used to detect abnormalities in cells, tissues (including bone marrow), spermatozoa, ova, blastomeres, oocysts, buccal cells and chorionic villi.

22. The probe set of claim 20, wherein the chromosome related abnormality is aneuploidy or polypliody.

20

23. The probe set of claim 10, wherein the probe set is used in preimplantation diagnosis or in prenatal screening.

25

24. The probe set of claim 10, wherein the probe set is used in a clinical diagnostic assay.

25

25. A probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome X in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

30

CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGG-CGC-AGA-GTT-TAA

(Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8) and TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9).

26. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
5 absence or number of human chromosome Y in a sample wherein the probing  
nucleobase sequence of at least one probe comprises a segment, at least a portion of  
which is, at least ninety percent homologous to the nucleobase sequences, or their  
complements, selected from the group consisting of:

10 CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-  
CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq.  
ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-  
AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq.  
ID No. 15) and GGC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16).

15 27. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
absence or number of human chromosome 1 in a sample wherein the probing nucleobase  
sequence of at least one probe comprises a segment, at least a portion of which is, at least  
ninety percent homologous to the nucleobase sequences, or their complements, selected  
from the group consisting of:

20 AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17) and CAT-TGA-ACA-GAA-TTG-  
AAT (Seq. ID No. 18).

25 28. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
absence or number of human chromosome 2 in a sample wherein the probing nucleobase  
sequence of at least one probe comprises a segment, at least a portion of which is, at least  
ninety percent homologous to the nucleobase sequences, or their complements, selected  
from the group consisting of:

30 GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC  
(Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-  
AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC  
(Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-  
TAA-GAT-TCT-AAG-AA (Seq. ID No. 25) and TCA-AAA-GAA-TGC-TTC-AAC-  
AC (Seq. ID No. 26).

29. A probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome 3 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least 5 ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-  
AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-  
GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG  
10 (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-  
AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-ACT-GAG (Seq. ID  
15 No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-  
ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37);  
CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-  
GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40);  
20 CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-  
AGA (Seq. ID No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID No. 43); GTG-  
AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq.  
25 ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-  
CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID No.  
30 48); and AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49);

30. A ~~probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome 6 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:~~

CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA  
(Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-  
AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID  
30 No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-  
CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57);  
GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-  
9

5  
CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-  
ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq.  
ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63) and TAC-CAA-  
GAG-GAA-TGT-TGC (Seq. ID No. 64).

10

31. A probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome 8 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

15  
ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-  
CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-  
AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT  
(Seq. ID No. 69) and CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70);

20

32. A probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome 10 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

25  
AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-  
TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73);  
TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-  
ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76) and GTA-  
GTT-GTT-GAG-AAT-GAT (Seq. ID No. 77).

30

33. A probe set comprising non-nucleic acid probes suitable for detecting the presence, absence or number of human chromosome 11 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

30  
AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-  
CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-

ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID No. 82) and GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83);

34. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
5 absence or number of human chromosome 12 in a sample wherein the probing  
nucleobase sequence of at least one probe comprises a segment, at least a portion of  
which is, at least ninety percent homologous to the nucleobase sequences, or their  
complements, selected from the group consisting of:

10 TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG  
(Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-  
TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq.  
ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-  
TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91);  
15 TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-  
AGT-TCT-TTG (Seq. ID No. 93); AAC-TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94);  
TGG-AGA-CAC-TGT-GTT-TGT (Seq. ID No. 95) and CCA-GTT-GGA-GAT-TTC-  
AAT (Seq. ID No. 96);

20 35. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
absence or number of human chromosome 16 in a sample wherein the probing  
nucleobase sequence of at least one probe comprises a segment, at least a portion of  
which is, at least ninety percent homologous to the nucleobase sequences, or their  
complements, selected from the group consisting of:

25 GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-  
ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-  
TAA-TGC-TAG-AGC-GAG (Seq. ID No. 100) and AAA-AAC-AAG-ACA-AAC-  
TCG (Seq. ID No. 101).

30 36. A probe set comprising non-nucleic acid probes suitable for detecting the presence,  
absence or number of human chromosome 17 in a sample wherein the probing  
nucleobase sequence of at least one probe comprises a segment, at least a portion of  
which is, at least ninety percent homologous to the nucleobase sequences, or their  
complements, selected from the group consisting of:

ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110) and AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111).

37. A probe set comprising non-nucleic acid probes suitable for detecting the presence,

absence or number of human chromosome 18 in a sample wherein the probing nucleobase sequence of at least one probe comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118).

38. A method for detecting, identifying or quantitating one or more of human chromosomes

Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 or 18 in a sample, said method comprising:

- a. contacting the sample with one or more non-nucleic acid probes having a probing nucleobase sequence which is specific for one or more of human chromosomes Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 or 18; and
- b. detecting, identify or quantitating hybridization of the probing nucleobase sequence of non-nucleic acid probes to the target sequences of the chromosomes, and correlating the result with the presence, absence or number of the chromosomes in the sample.

39. The method of claim 38, wherein the probing nucleobase sequence of at least one probe of the set comprises a segment, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-  
AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-  
CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID  
No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-  
AGA-TTG-AAC-CTT (Seq. ID No. 15); GGC-ATA-GCA-CAT-AAC-ATG (Seq.  
ID No. 16); AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17); CAT-TGA-  
ACA-GAA-TTG-AAT (Seq. ID No. 18); GTT-TTC-AGG-GGA-AGA-TAT (Seq.  
ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-CCT-  
TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A  
(Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-  
TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-  
AAG-AAT (Seq. ID No. 25); TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID  
No. 26); ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-  
TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq.  
ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-  
GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA  
(Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-  
AAA-GCA-GTT-ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-  
ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36);  
CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-  
AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No.  
39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-  
TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-AGA (Seq. ID  
No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID No. 43); GTG-AAA-GTT-  
CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID  
No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-  
CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID  
No. 48); AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49); CTG-TTC-AGA-  
GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID  
No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-  
AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq.  
ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-  
TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq.

5 ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63); TAC-CAA-GAG-GAA-TGT-TGC (Seq. ID No. 64); ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq. ID No. 69); CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70); AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76); GTA-GTT-GTT-GAG-AAT-GAT (Seq. ID No. 77); AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID No. 82); GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83); TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT (Seq. ID No. 95); CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100); AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID No. 101); ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-

10

15

20

25

30

5 ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110); AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118).

10

15 40. A method for detecting, identifying or quantitating one or more of human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 or 18 in a sample, said method comprising:

20 a. contacting the sample with one or more non-nucleic acid probes having a probing nucleobase sequence at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of: CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGC-CGC-AGA-GTT-TAA (Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8); TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9); CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq. ID No. 15); GGC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16); AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17); CAT-TGA-ACA-GAA-TTG-AAT (Seq. ID No. 18); GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-AAG-AAT (Seq. ID No. 25); TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID No. 26); ATA-ATT-

25

30

AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-AGA (Seq. ID No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID No. 48); AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49); CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63); TAC-CAA-GAG-GAA-TGT-TGC (Seq. ID No. 64); ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq. ID No. 69); CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70); AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76); GTA-GTT-GAG-AAT-

5  
10  
15  
20  
25  
30

*Sub B3 with*

GAT (Seq. ID No. 77); AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-  
5 CTT-GAA-ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG  
(Seq. ID No. 80); GTC-ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-  
TCC-TGT-TGA-CAG-A (Seq. ID No. 82); GTT-TGA-AAG-CTG-AAC-TAT-G  
(Seq. ID No. 83); TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-  
AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA  
(Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-  
10 TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG  
(Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-  
TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG  
(Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-  
15 TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT  
(Seq. ID No. 95); CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); GAA-GCC-  
TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-ACC (Seq.  
ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-  
TAG-AGG-GAG (Seq. ID No. 100); AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID  
20 No. 101); ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-  
TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID  
No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-  
ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID  
25 No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-  
AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID  
No. 110); AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); TTC-CCG-TAA-  
CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID  
30 No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-  
TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID  
No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-  
AAC-TTA-CTC-GTG (Seq. ID No. 118); and

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of non-nucleic acid probes to the target sequences of the chromosomes, and correlating the result with the presence, absence or number of the chromosomes in the sample.

41. The method of claim 40, wherein the presence, absence or number of human chromosome X is determined by:

5 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

10 CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGC-CGC-AGA-GTT-TAA (Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8) and TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9); and

15 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human X chromosomes in the sample.

20 42. The method of claim 40, wherein the presence, absence or number of human chromosome Y is determined by:

25 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

30 CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq. ID No. 15) and GGC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16); and

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human Y chromosomes in the sample.

43. The method of claim 40, wherein the presence, absence or number of human chromosome 1 is determined by:

5 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17) and CAT-TGA-ACA-GAA-TTG-AAT (Seq. ID No. 18); and

10 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 1 in the sample.

15 44. The method of claim 40, wherein the presence, absence or number of human chromosome 2 is determined by:

20 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-AAG-AA (Seq. ID No. 25) and TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID No. 26); and

25 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 2 in the sample.

30 45. The method of claim 40, wherein the presence, absence or number of human chromosome 3 is determined by:

5

*Sub of canceled*

a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

10

ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-GAC-TTC-AGA-AAC-AGA (Seq. ID No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID No. 48); and AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49); and

15

20

25

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 3 in the sample.

30

46. The method of ~~claim 40~~, wherein the presence, absence or number of human chromosome 6 is determined by:

a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

35

CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); and

52); TCT-AGG-AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63) and TAC-CAA-GAG-GAA-TGT-TGC (Seq. ID No. 64); and

10 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 6 in the sample.

15 47. The method of claim 40, wherein the presence, absence or number of human chromosomes 8 is determined by:

20 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

25 ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq. ID No. 69) and CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70); and

30 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 8 in the sample.

48. The method of claim 40, wherein the presence, absence or number of human chromosomes 10 is determined by:

5 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

10 AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76) and GTA-GTT-GTT-GAG-AAT-GAT (Seq. ID No. 77); and

15 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 10 in the sample.

20 *Sub 11*  
25 49. The method of claim 40, wherein the presence, absence or number of human chromosome 11 is determined by:

a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

30 AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID No. 82) and GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83); and

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 11 in the sample.

35 50. The method of claim 40, wherein the presence, absence or number of human chromosome 12 is determined by:

a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

5 TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-  
AGA-AAG (Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-TTG-AAT-  
AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-TTA-  
10 GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-  
TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT  
15 (Seq. ID No. 95) and CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); and

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 12 in the sample.

20 51. The method of claim 40, wherein the presence, absence or number of human chromosome 16 is determined by:

25 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-  
GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100) and AAA-AAC-  
30 AAG-ACA-AAC-TCG (Seq. ID No. 101); and

b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 16 in the sample.

52. The method of claim 40, wherein the presence, absence or number of human chromosome 17 is determined by:

5 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

10 ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-  
15 ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110) and AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); and

20 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 17 in the sample.

25 53. The method of claim 40, wherein the presence, absence or number of human chromosome 18 is determined by:

20 a. contacting the sample with one or more non-nucleic acid probes, wherein at least one probe has a probing nucleobase sequence, at least a portion of which is at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of:

25 TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118); and

30 b. detecting, identifying or quantitating hybridization of the probing nucleobase sequence of the probe to a target sequence in the sample to thereby correlate the result with the presence, absence or number of human chromosome 18 in the sample.

54. The method of claim 40, wherein the two or more probes are unlabeled.

55. The method of claim 40, wherein at least one probe is labeled with a detectable moiety.

56. The method of claim 55, wherein the detectable moiety or moieties are selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound.

10 57. The method of claim 40, wherein *in-situ* hybridization is used to detect, identify or enumerate human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18 in the sample.

15 58. The method of claim 40, wherein the method is used to detect or identify chromosome related abnormalities.

20 59. The method of claim 40, wherein the method is used to detect abnormalities in cells, tissues (including bone marrow), spermatozoa, ova, blastomeres, oocysts, buccal cells and chorionic villi.

60. The method of claim 58, wherein the chromosome related abnormality is aneuploidy or polyploidy.

25 61. The method of claim 40, wherein the method is used in preimplantation diagnosis or in prenatal screening.

62. The method of claim 40, wherein the method is used in a clinical diagnostic assay.

30 63. The method of claim 49, wherein analysis of *in-situ* hybridized specimens is performed using a microscope and camera, a flow cytometer or a slide-based analysis system.



5

15

20

25

30

No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID No. 48); AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49); CTG-TTC-AGA-GTA-ACA-TGA (Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID No. 51); GAA-ATG-GAA-ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-AGG-TCC-AAT-TAT (Seq. ID No. 53); GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq. ID No. 55); AAG-GAG-TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-CTC-TAA (Seq. ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63); TAC-CAA-GAG-GAA-TGT-TGC (Seq. ID No. 64); ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No. 65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA (Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-GCT-GAA-CAT (Seq. ID No. 69); CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70); AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No. 75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76); GTA-GTT-GTT-GAG-AAT-GAT (Seq. ID No. 77); AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID No. 82); GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83); TCC-TGT-AAT-GTT-CGA-CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-TTT-CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq. ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq. ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-TGC-ACA-AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT (Seq. ID No. 95); CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-

*(10) See page 10*

AGC-ATT-CTG-GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100); AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID No. 101); ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110); AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118); and

b. other reagents or compositions necessary to perform the assay.

65. The kit of claim 64, wherein at the probe or probes are unlabeled.

66. The kit of claim 65, wherein hybridization of the probing nucleobase sequence of the probe to the chromosome is detected using an antibody or antibody fragment, wherein the antibody or antibody fragment specifically binds, under antibody binding conditions, to the PNA/nucleic acid complex which forms under suitable hybridization conditions.

67. The kit of claim 66, comprising an antibody labeled with a detectable moiety.

68. The kit of claim 67, wherein the detectable moiety is selected from the group consisting of a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound.

69. The kit of claim 64, wherein at least one non-nucleic acid probe is labeled with a detectable moiety.

5 70. The kit of claim 69, wherein the detectable moiety or moieties are selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound.

71. The kit of claim 64, wherein *in-situ* hybridization is used to detect, identify or enumerate human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18 in the sample.

10 72. The kit of claim 71, wherein analysis of *in-situ* hybridized specimens is performed using a microscope and camera, a flow cytometer or a slide based analysis system.

15 73. The kit of claim 64, wherein the kit is used to detect or identify chromosome related abnormalities.

74. The kit of claim 64, wherein the kit is used to detect abnormalities in cells, tissues (including bone marrow, spermatozoa, ova, blastomeres, oocysts, buccal cells and chorionic villi.

20 75. The kit of claim 64, wherein the chromosome related abnormality is aneuploidy or polyploidy.

76. The kit of claim 64, wherein the kit is used in preimplantation diagnosis or in prenatal screening.

25 77. The kit of claim 64, wherein the kit is used in a clinical diagnostic assay.

78. A multiplex assay using non-nucleic acid probes to detect, identify or enumerate two or more human chromosomes in the sample.

30 79. The multiplex assay of claim 78, wherein the assay is used to detect, identify or enumerate two or more human chromosomes selected from the group consisting of: X, Y, 1, 2, 3, 6, 8, 10, 11, 12, 16, 17 and 18.

80. The multiplex assay of claim 78, wherein at least two non-nucleic acid probes are independently detectable such that each of the two or more probes can detect the presence, absence or number of one of human chromosomes X, Y, 1, 2, 3, 6, 8, 10, 11, 12,

5 16, 17 or 18.

81. The multiplex assay of claim 80, wherein one or more of the non-nucleic acid probes comprise a probing nucleobase sequence, at least a portion of which is, at least ninety percent homologous to the nucleobase sequences, or their complements, selected from the group consisting of: CTT-CAA-AGA-GGT-CCA-CGA (Seq. ID No. 1); AGG-GTT-CAA-CTG-TGT-GAC (Seq. ID No. 2); GAA-ACT-TCT-GAG-TGA-TGA (Seq. ID No. 3); CAG-TCA-TCG-CAG-AAA-ACT (Seq. ID No. 4); AGA-TTT-CAC-TGG-AAA-CGG (Seq. ID No. 5); GTT-ATG-GGA-AGG-TGA-TCC (Seq. ID No. 6); TCG-AGC-CGC-AGA-GTT-TAA (Seq. ID No. 7); CTA-TTT-AGC-GGG-CTT-GGA (Seq. ID No. 8); TAC-AAG-GGT-GTT-GCA-AAC (Seq. ID No. 9); CCA-TAT-GCA-GTT-ATA-AGT-AGG (Seq. ID No. 10); TAT-TGT-ACC-AAG-CAG-AGT-ACC (Seq. ID No. 11); GGT-ATA-TAT-AAG-ATG-ACA-CAG-GA (Seq. ID No. 12); GTT-AGT-TAT-ATT-GGG-TGA-TAT-GT (Seq. ID No. 13); TCA-CAT-AAT-AGA-CAA-CAT-AC (Seq. ID No. 14); CAG-AAG-AGA-TTG-AAC-CTT (Seq. ID No. 15); GGC-ATA-GCA-CAT-AAC-ATG (Seq. ID No. 16); AAT-CGT-CAT-CGA-ATG-AAT (Seq. ID No. 17); CAT-TGA-ACA-GAA-TTG-AAT (Seq. ID No. 18); GTT-TTC-AGG-GGA-AGA-TAT (Seq. ID No. 19); TGT-GCG-CCC-TCA-ACT-AAC (Seq. ID No. 20); GAA-GCT-TCA-TTG-GGA-TGT (Seq. ID No. 21); CCA-ATA-AAA-GCT-ACA-TAG-A (Seq. ID No. 22); GAA-AAA-GTT-TCT-GAC-ATT-GC (Seq. ID No. 23); TAG-TTG-AAG-GGC-ACA-TCA (Seq. ID No. 24); CAC-AAA-TAA-GAT-TCT-AAG-AAT (Seq. ID No. 25); TCA-AAA-GAA-TGC-TTC-AAC-AC (Seq. ID No. 26); ATA-ATT-AGA-CCG-GAA-TCA-T (Seq. ID No. 27); GCT-GTT-TTC-TAA-AGG-AAA-G (Seq. ID No. 28); AAG-ACT-TCA-AAG-AGG-TCC (Seq. ID No. 29); TTT-GTC-AAG-AAT-TAT-AAG-AAG (Seq. ID No. 30); CAA-GAT-TGC-TTT-TAA-TGG (Seq. ID No. 31); TGT-GTA-TCA-ACT-CAC-GGA (Seq. ID No. 32); CCT-CAC-AAA-GTA-GAA-ACT (Seq. ID No. 33); GAA-AAA-GCA-GTT-ACT-GAG (Seq. ID No. 34); TAA-TAA-TTA-GAC-GGA-ATC-AT (Seq. ID No. 35); TTA-CAG-GGC-ATT-GAA-GCC (Seq. ID No. 36); CAG-TTA-TGA-AGC-AGT-CTC (Seq. ID No. 37); CAC-ACC-AGA-AAA-AGC-AGT (Seq. ID No. 38); AAG-GGT-AAA-CAC-TGT-GAG (Seq. ID No. 39); AGA-CAA-CGA-AAT-ATC-

TTC-ATG (Seq. ID No. 40); CTA-GCA-GTA-TGA-GGT-CAA (Seq. ID No. 41); GCA-  
GAC-TTC-AGA-AAC-AGA (Seq. ID No. 42); GGC-CTC-AAA-GAC-GTT-TAA (Seq. ID  
No. 43); GTG-AAA-GTT-CCA-AGT-GAA (Seq. ID No. 44); GAG-TGC-TTT-GAA-GCC-  
TAC (Seq. ID No. 45); GAA-ACA-GCA-GAG-TTG-AAA (Seq. ID No. 46); TGC-AGA-  
5 GAT-CAC-AAC-GTG (Seq. ID No. 47); ACA-AAG-AAT-CAT-TCG-CAG (Seq. ID No.  
48); AGT-GTT-AGA-AAA-CTG-CTC (Seq. ID No. 49); CTG-TTC-AGA-GTA-ACA-TGA  
(Seq. ID No. 50); CCG-CTT-GGA-AAT-ACT-ACA (Seq. ID No. 51); GAA-ATG-GAA-  
ATA-TCT-CCC-C (Seq. ID No. 52); TCT-AGG-AGG-TCC-AAT-TAT (Seq. ID No. 53);  
GAA-TTC-CCA-AGT-GGA-TAT (Seq. ID No. 54); CTG-TAG-GTT-TAG-ATG-AAG (Seq.  
10 ID No. 55); AAG-GAG-TGT-TTC-CCA-ACT (Seq. ID No. 56); GGC-TTC-AAG-GCG-  
CTC-TAA (Seq. ID No. 57); GCA-GAG-ACT-TCA-AAG-TGC (Seq. ID No. 58); CAC-  
ACA-CAC-GGT-GGA-CCA (Seq. ID No. 59); CAA-AGG-GAA-TGT-TCC-ATT (Seq. ID  
No. 60); CAC-ATA-GCA-GTG-TTT-GAG (Seq. ID No. 61); CTC-AAG-GCG-GTC-CAA-  
TTA (Seq. ID No. 62); GAG-TCG-AAA-TGC-ACA-CAT (Seq. ID No. 63); TAC-CAA-  
15 GAG-GAA-TGT-TGC (Seq. ID No. 64); ACG-GGA-TGC-AAT-ATA-AAA (Seq. ID No.  
65); TGA-AGA-TTC-TGC-ATA-CGG (Seq. ID No. 66); AAG-GTT-TGT-ACT-GAC-AGA  
(Seq. ID No. 67); CTG-AAC-TAT-GGT-GAA-AAA (Seq. ID No. 68); ACT-AAC-TGT-  
GCT-GAA-CAT (Seq. ID No. 69); CCC-ATG-AAT-GCG-AGA-TAG (Seq. ID No. 70);  
AAC-TGA-ACG-CAC-AGA-TGA (Seq. ID No. 71); GGC-TAA-TCT-TTG-AAA-TTG-  
20 AAA (Seq. ID No. 72); AGG-TGG-ATA-ATT-GGC-CCT (Seq. ID No. 73); TGA-AGT-  
CCA-AAA-AAG-CAC (Seq. ID No. 74); CTT-AGA-CAT-GGA-AAT-ATC (Seq. ID No.  
75); AAG-GGG-TCT-AAC-TAA-TCA (Seq. ID No. 76); GTA-GTT-GTT-GAG-AAT-GAT  
(Seq. ID No. 77); AAC-TTC-CCA-GAA-CTA-CAC (Seq. ID No. 78); ATT-CTT-GAA-  
ATG-GAA-CAC (Seq. ID No. 79); CTG-TGA-TTG-CTG-ATT-TGG (Seq. ID No. 80); GTC-  
25 ATC-ACA-GGA-AAC-ATT (Seq. ID No. 81); GAA-ATT-TCC-TGT-TGA-CAG-A (Seq. ID  
No. 82); GTT-TGA-AAG-CTG-AAC-TAT-G (Seq. ID No. 83); TCC-TGT-AAT-GTT-CGA-  
CAG (Seq. ID No. 84); TCA-TAG-AAC-GCT-AGA-AAG (Seq. ID No. 85); ACC-TTT-  
CTT-TTG-ATG-AAG-GA (Seq. ID No. 86); CAA-ATA-TCA-CAA-AAA-GAG-GG (Seq.  
ID No. 87); GAG-TTG-AAT-AGA-GGC-AAC (Seq. ID No. 88); GGC-CAA-ATG-TAG-  
30 AAA-AGG (Seq. ID No. 89); GCG-TTC-AAC-TCA-AGG-TGT (Seq. ID No. 90); TGT-  
CCT-TTA-GAC-AGA-GCA (Seq. ID No. 91); TGA-GAC-CAA-ATG-TAC-AAA-AG (Seq.  
ID No. 92); GAA-TAC-TGA-GTA-AGT-TCT-TTG (Seq. ID No. 93); AAC-TGC-ACA-  
AAT-AGG-GTG (Seq. ID No. 94); TGG-AGA-CAC-TGT-GTT-TGT (Seq. ID No. 95);

CCA-GTT-GGA-GAT-TTC-AAT (Seq. ID No. 96); GAA-GCC-TGC-CAG-TGG-ATA (Seq. ID No. 97); TAC-AGC-ATT-CTG-GAA-ACC (Seq. ID No. 98); CCA-GAC-ACT-GCG-TAG-TGA (Seq. ID No. 99); ATA-TAA-TGC-TAG-AGG-GAG (Seq. ID No. 100); AAA-AAC-AAG-ACA-AAC-TCG (Seq. ID No. 101); ATT-TCA-GCT-GAC-TAA-ACA (Seq. ID No. 102); AAC-GAA-TTA-TGG-TCA-CAT (Seq. ID No. 103); GGT-GAC-GAC-TGA-GTT-TAA (Seq. ID No. 104); TTT-GGA-CCA-CTC-TGT-GGC (Seq. ID No. 105); AAC-GGG-ATA-ACT-GCA-CCT (Seq. ID No. 106); TTT-GTG-GTT-TGT-GGT-GGA (Seq. ID No. 107); AGG-GAA-TAG-CTT-CAT-AGA (Seq. ID No. 108); ATC-ACG-AAG-AAG-GTT-CTG (Seq. ID No. 109); CCG-AAG-ATG-TCT-TTG-GAA (Seq. ID No. 110); AAA-GAG-GTC-TAC-ATG-TCC (Seq. ID No. 111); TTC-CCG-TAA-CAA-CTA-TGC (Seq. ID No. 112); TCC-CGT-AAC-AAC-TAG-GCA (Seq. ID No. 113); AAA-AGG-AGT-GAT-CCA-ACC (Seq. ID No. 114); TCC-CTT-TGG-TAG-AGC-AGG (Seq. ID No. 115); ATT-TGA-GAT-GTG-TGT-ACT-CA (Seq. ID No. 116); GCA-CTT-ACC-GGC-CTA-AG (Seq. ID No. 117) and CTC-AGA-AAC-TTA-CTC-GTG (Seq. ID No. 118).

15 82. The multiplex assay of claim 78, wherein the assay is used in preimplantation diagnosis or in prenatal screening.

20 83. A non-nucleic acid probe comprising two or more linked independently detectable moieties wherein the combination of the two or more independently detectable moieties is used to identify a particular probe/target sequence hybrid suitable for detecting, identifying or enumerating human chromosomes.

25 84. The probe of claim 83, wherein the two or more linked independently detectable moieties are independently detectable fluorophores.

85. The probe of claim 83, wherein the probe is a PNA.

30 86. The probe of claim 83, wherein the probe is used in preimplantation diagnosis or in prenatal screening.